Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Drug Deliv Transl Res. 2011 Jun 1;1(3):209–222. doi: 10.1007/s13346-011-0022-6

Figure 1.

Figure 1

Figure 1

(A) P4R5 cells were exposed to varying concentrations of dapivirine or UC781, and then immediately inoculated with HIV-1 in the continued presence of the drug. The extent of infection was assessed after 48h using a fluorescence-based β-galactosidase detection assay using 4-methyllumbelliferyl-β-D-galactopyranoside. Dapivirine showed greater potency than UC781 in single HIV-1 replication cycle assays using the P4R5 indicator cell line. Dapivirine EC50 is 1 nM and UC781 EC50 is 5 nM. (B) P4R5 cells were exposed to varying concentrations of dapivirine or UC781 for 18h. The medium was removed and the cells were extensively washed and inoculated with HIV-1 virus in the absence of exogenous drug. The extent of infection was assessed after 48h. Both dapivirine and UC781 were able to establish a protective barrier to infection in P4R5 cells following drug pretreatment and subsequent exposure to HIV-1 in the absence of exogenous drug. Dapivirine showed greater potency than UC781 in this context.